Concentration-dependent QT-interval prolongation after citalopram intoxication and factors influencing citalopram concentration in everyday clinical practice;Konzentrationsabhängige QT-zeit-verlängerung bei citalopram-intoxikation und einflussgrößen auf die citalopram-konzentration im klinischen alltag: Fallbericht und ergebnisse eines therapeutischen drug-monitorings (TDM) unter naturalistischen bedingungen

Psychopharmakotherapie

Volumn 19, Issue 3, 2012, Pages 123-128

  Unterecker, Stefan ^a   Warrings, Bodo ^a   Deckert, Jürgen ^a   Pfuhlmann, Bruno ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Citalopram; Intoxication; QT interval; Therapeutic drug monitoring

Indexed keywords

CITALOPRAM;

ADULT; CASE REPORT; CLINICAL PRACTICE; DRUG BLOOD LEVEL; DRUG INTOXICATION; ELECTROCARDIOGRAM; FEMALE; HUMAN; MEDICAL RECORD REVIEW; QT PROLONGATION; REVIEW; SUICIDAL IDEATION;

EID: 84862749653     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Baranchuk A, Simpson CS, Methot M, Gibson K, et al. Corrected QT interval prolongation after overdose of escitalopram, morphine, oxycodone, zopiclone and benzodiazepines. Can J Cardiol 2008;24:38-40.
2. Brøsen K, Naranjo CA. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol 2001;11:275-83.
3. Catalano G, Catalano MC, Epstein MA, Tsambiras PE. QTc interval prolongation associated with citalopram overdose: a case report and literature review. Clin Neuropharmacol 2001;24:158-62.
4. Drasch G, Dahlmann F, von Meyer L, Roider G, et al. Frequency of different anti-depressants associated with suicides and drug deaths. Int J Legal Med 2008;122:115-21.
5. Flanagan RJ. Fatal toxicity of drugs used in psychiatry. Hum Psychopharmacol Clin Exp 2008;23:43-51.
6. Friberg LE, Isbister GK, Duffull SB. Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses. Br J Clin Pharmacol 2005;61:177-90.
7. Glassman AH. Citalopram toxicity [letter]. Lancet 1997;350:818.
8. Grundemar L, Wohlfart B, Lagerstedt C, Bengtsson F, et al. Symptoms and signs of severe citalopram overdose [letter]. Lancet 1997;349:1602.
9. Hale AS. Citalopram is safe [letter]. Br Med J 1998;316:1825.
10. Hamplová-Peichlová J, Krůsek J, Paclt I, Slavícek J, et al. Citalopram inhibits L-type calcium channel current in rat cardiomyocytes in culture. Physiol Res 2002;51:317-21.
11. Hawton K, Bergen H, Simkin S, Cooper J, et al. Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. Br J Psychiatry 2010;196:354-8.
12. Hayes BD, Klein-Schwartz W, Clark RF, Muller AA, et al. Comparison of toxicity of acute overdoses with citalopram and escitalopram. J Emerg Med 2010;39:44-8.
13. Hiemke C, Baumann P, Bergemann N, Conca A, et al. AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry 2011;44:195-235.
14. Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 2004;42:277-85.
15. Jimmink A, Caminada K, Hunfeld NG, Touw DJ. Clinical toxicology of citalopram after acute intoxication with the sole drug or in combination with other drugs: over- view of 26 cases. Ther Drug Monit 2008;30:365-71.
16. Kelly CA, Dhaun N, Laing WJ, Strachan FE, et al. Comparative toxicity of Citalopram and the newer antidepressants after overdose. J Toxicol Clin Toxicol 2004;42:67-71.
17. Lundbeck GmbH. Rote-Hand-Brief vom 31.10.2011 zu Citalopram (Cipramil®): Zusammenhang von Cipramil® (Citalopramhydrobromid/ Citalopramhydrochlorid) mit dosisabhängiger QT-Intervall-Verlängerung, http:/www.bfarm.de/DE/Pharmakovigilanz/stufenplanverf/Liste/stp-citalopram. html.
18. Lundbeck GmbH. Rote-Hand-Brief vom 05.12.2011 zu Cipralex® (Escitalopram): Zusammenhang von Escitalopram (Cipralex®) mit dosisabhängiger QT-Intervall-Verlängerung. http://www.akdae.de/ Arzneimittelsicherheit/RHB/20111205.pdf.
19. Noord C van, Straus SM, Sturkenboom MC, Hofman A, et al. Psychotropic drugs associated with corrected QT interval prolongation. J Clin Psychopharmacol 2009;29:9-15.
20. Öström M, Eriksson A, Thorson J, Spigset O. Fatal overdose with Citalopram. Lancet 1996;348:339-40.
21. Pacher P, Ungvari Z, Nanasi PP, Furst S, et al. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Curr Med Chem 1999;6:469-80.
22. Pedersen OL, Gram LF, Kristensen CB, Moller M, et al. Overdosage of antidepressants: clinical and pharmacokinetic aspects. Eur J Clin Pharmacol 1982;23:513-21.
23. Personne M, Persson H, Sjoberg G. Citalopram toxicity. Lancet 1997;350:518-9.
24. Personne M, Sjoberg G, Persson H. Citalopram overdose: review of cases treated in Swedish hospitals. J Toxicol Clin Toxicol 1997;35:237-40.
25. Pfuhlmann B, Gerlach M, Burger R, Gonska S, et al. Therapeutic drug monitoring of tricyclic antidepressants in everyday clinical practice. J Neural Transm Suppl 2007;72:287-96.
26. Rasmussen SL, Overo KF, Tanghoj P. Cardiac safety of citalopram: prospective trials and retrospective analyses. J Clin Psychopharmacol 1999;19:407-15.
27. Reis M, Aamo T, Spigset O, Ahlner J. Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther Drug Monit 2009;31:42-56.
28. Slavícek J, Paclt I, Hamplová J, Kittnar O, et al. Antidepressant drugs and heart electrical field. Physiol Res 1998;47:297-300.
29. Unverir P, Atilla R, Karcioglu O, Topacoglu H, et al. A retrospective analysis of antidepressant poisonings in the emergency department: 11-year experience. Hum Exp Toxicol 2006;25:605-12.
30. Waring WS, Gray JA, Graham A. Predictive factors for generalized seizures after deliberate citalopram overdose. Br J Clin Pharmacol 2008;66:861-5.
31. Witchel HJ, Pabbathi VK, Hofmann G, Paul AA, et al. Inhibitory actions of the selective serotonin re-uptake inhibitor Citalopram on HERG and ventricular L-type calcium currents. FEBS Lett 2002;512:59-66.
32. BfArM. Abwehr von Gefahren durch Arzneimittel, Stufe II. Citalopram (oder dessen Derivate) und dosisabhängige QT-Intervall-Verlängerung: Änderungen und Ergänzungen in den Produktinformationen, Negatives Nutzen-Risiko-Verhältnis der 60mg-Stärke (Bescheid vom 15. März 2012). http://www.bfarm.de/SharedDocs/1-Downloads/DE/Pharmakovigilanz/ stufenplverf/citalopram-bescheid. pdf?--blob=publicationFile